Integra LifeSciences Holdings Corporation

NasdaqGS:IART 주식 보고서

시가총액: US$1.0b

Integra LifeSciences Holdings 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mojdeh Poul

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기less than a year
CEO 소유권n/a
경영진 평균 재임 기간4.8yrs
이사회 평균 재임 기간12yrs

최근 관리 업데이트

Recent updates

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 27
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Looks Inexpensive But Perhaps Not Attractive Enough

Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade)

Mar 06

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Extensively

Jan 31
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Extensively

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Nov 05
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Oct 24
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
author-image

LifeSciences' Strategic Moves To Boost Quality And Compliance For Long-term Profit Growth

Sep 24 Investing in compliance and quality improvements aims to enhance product supply reliability and support long-term revenue growth by meeting market demand.

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Sep 08
Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24
Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22
Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15
Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03
Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19
Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05
Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26
Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14
At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27
Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

CEO

Mojdeh Poul (61 yo)

less than a year

테뉴어

Ms. Mojdeh Poul is President, CEO & Director of Integra LifeSciences Holdings Corporation from January 6, 2025. Ms. Poul serves as Independent Director at iRhythm Technologies, Inc. since June 1, 2023. She...


리더십 팀

이름위치테뉴어보상소유권
Stuart Essig
Non- Executive Chairman27.4yrsUS$465.03k2.27%
$ 23.4m
Lea Knight
Executive VP & CFO1.9yrsUS$3.15m0.079%
$ 816.7k
Robert Davis
Executive VP & President of Tissue Technologies12.4yrsUS$2.26m0.098%
$ 1.0m
Michael McBreen
Executive VP & President of Codman Specialty Surgical5yrsUS$3.16m0.091%
$ 939.8k
Harvinder Singh
Executive VP & President of International Business2.6yrsUS$2.62m0.017%
$ 177.0k
Mojdeh Poul
Presidentless than a year데이터 없음데이터 없음
Stephen Leonard
Corporate VP of Global Operations & Supply Chain4.8yrs데이터 없음데이터 없음
Jeffrey Mosebrook
Senior VP of Finance & Principal Accounting Officer7.6yrsUS$1.25m0.053%
$ 546.1k
Christopher Ward
Senior Director of Investor Relationsno data데이터 없음데이터 없음
Eric Schwartz
Executive VP6.5yrsUS$1.62m0.073%
$ 748.4k
Laurene Isip
Vice President of Global Corporate Communications & Public Relationsno data데이터 없음데이터 없음
Ruth Fleming
Vice President of Global Marketingno data데이터 없음데이터 없음

4.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: IART 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Stuart Essig
Non- Executive Chairman27.4yrsUS$465.03k2.27%
$ 23.4m
Mojdeh Poul
Presidentless than a year데이터 없음데이터 없음
Raymond Murphy
Independent Director16.1yrsUS$300.01k0.11%
$ 1.1m
Christian Schade
Independent Director19.3yrsUS$335.01k0.082%
$ 848.3k
Barbara Hill
Independent Presiding Director12yrsUS$348.78k0.18%
$ 1.8m
Keith N. Bradley
Independent Director33.3yrsUS$295.01k0.091%
$ 934.3k
Jeffrey Graves
Independent Director1.4yrsUS$312.87k0.016%
$ 166.9k
Shaundra Clay
Independent Director4.1yrsUS$300.01k0.028%
$ 292.9k
Renee Lo
Independent Director2.8yrsUS$300.01k0.021%
$ 215.8k

12.0yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: IART 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 12 년).


기업 분석 및 재무 데이터 현황

데이터마지막 업데이트(UTC 시간)
기업 분석2025/05/06 03:42
장 마감 주가2025/05/06 00:00
수익2025/03/31
연간 수익2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
회사 재무10년
  • 손익 계산서
  • 현금 흐름표
  • 대차 대조표
애널리스트 컨센서스 추정치+3년
  • 재무 예측
  • 애널리스트 목표가
시장 가격30년
  • 주식 가격
  • 배당금, 분할 및 액션
소유권10년
  • 최대 주주
  • 내부자 거래
관리10년
  • 리더십 팀
  • 이사회
주요 개발 사항10년
  • 회사 공지 사항

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Integra LifeSciences Holdings Corporation 31 애널리스트 중 11 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가교육기관
David ToungArgus Research Company
Matthew TaylorBarclays
Charley JonesBarrington Research Associates, Inc.